**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 74674

**Manuscript Type:** CASE REPORT

**Gitelman syndrome: A case report**

Shi-Yuan Chen *et al*. Diagnose Gitelman syndrome

Shi-Yuan Chen, Ning Jie

**Shi-Yuan Chen, Ning Jie,** Department of Endocrinology, Longhua Central Hospital, Shenzhen 518110, Guangdong Province, China

**Author contributions:** Chen SY and Ning J analyzed the data and diagnosed Gitelman syndrome; Chen SY wrote the manuscript; Ning J modified this manuscript.

**Corresponding author: Ning Jie, MD, Chief Doctor,** Department of Endocrinology, Longhua Central Hospital, No. 187 Guanlan Avenue, Shenzhen 518110, Guangdong Province, China. jiening919@gmail.com

**Received:** January 1, 2022

**Revised:** February 24, 2022

**Accepted: April 4, 2022**

**Published online:**

**Abstract**

BACKGROUND

Gitelman syndrome (GS) is an autosomal recessive salt-losing renal tubulopathy arising from mutations in the thiazide-sensitive Na-Cl cotransporter (*NCC*) gene. Due to its low incidence and lack of awareness, GS can be easily misdiagnosed or missed in diagnosis.

CASE SUMMARY

A 24-year-old male presented with > 4 years of repeated limb weakness without any treatment. The previous day, the patient was bitten by ants and showed weakness of the lower limbs. The patient had hypokalemia (1.66-2.83 mmol/L), hypomagnesemia (0.4 mmol/L), hypocalciuria (1.51-2.46 mmol/d), metabolic alkalosis (7.47-7.54), normal blood pressure, and increased activity of aldosterone and plasma renin activity (PRA) (PRA 6.4 and 16.45 ng/mL/h and aldosterone 330.64 and 756.82 pg/mL in the supine and upright position, respectively). In addition, *SLCI2A3* gene mutation with GS was diagnosed. Oral and intravenous supplementation with potassium and magnesium was initiated. Serum magnesium returned to 0.48 mmol/L and serum potassium returned to 3.08 mmol/L, alleviating the patient’s fatigue symptoms.

CONCLUSION

GS should be considered in patients with hypokalemia complicated with hypomagnesemia. Genetic testing is essential to confirm the diagnosis.

**Key Words:** Gitelman syndrome; Limb weakness; Hypokalemia; Hypomagnesemia; Hypocalciuria; Genetic testing; Case report

Chen SY, Jie N. Gitelman syndrome: A case report. *World J Clin Cases* 2022; In press

**Core Tip:** Gitelman syndrome (GS) is easily misdiagnosed or missed in diagnosis due to its low incidence and lack of awareness. Herein, we present a rare case of GS in a young man with limb weakness. This case demonstrates that attention should be focused on GS in patients with hypokalemia complicated with hypomagnesemia. Genetic testing is helpful in confirming the diagnosis.

**INTRODUCTION**

Gitelman syndrome (GS) is characterized by low blood potassium, low blood magnesium, low blood chloride, low urinary calcium, normal or low blood pressure, alkalosis, and activation of the renin-angiotensin-aldosterone system (RAAS), which are the clinical manifestations of autosomal recessive salt-losing renal tubular disease, also known as familial hypokalemia and hypomagnesemia[1]. The incidence of GS is low and is reported to be approximately 1/40000 in Europeans[2], and 10.3/10000 in Japanese[3] based on the heterozygous carrier rate, and is easily misdiagnosed or missed in diagnosis. We here report a case of GS diagnosed and treated in the Department of Endocrinology, Longhua District Central Hospital, Shenzhen, China.

**CASE PRESENTATION**

***Chief complaints***

A 24-year-old male presented with > 4 years of repeated limb weakness and a relapse of 1 d.

***History of present illness***

Four years ago, the patient developed limb weakness and fatigue, especially in the lower limbs, which could be relieved spontaneously after rest. He could walk and hold objects with both hands. During the period without a specific diagnosis and treatment, the above symptoms occasionally occurred without aggravation but could be relieved spontaneously after rest. One day ago, the patient was bitten by ants and showed weakness in the lower limbs. His blood potassium level was 1.66 mmol/L when examined in the Emergency Department. Following oral and intravenous potassium supplementation and intravenous magnesium supplementation, his blood potassium was reexamined and was found to be 2.22 mmol/L, and the patient was admitted to our department with hypokalemia.

***History of past illness***

The patient had no medical history.

***Personal and family history***

No member of the patient’s immediate or extended family reported similar symptoms. He denied the use of any herbal medicine, diuretics, or laxatives.

***Physical examination***

Physical examination revealed a thin man, 156 cm in height, and 33.5 kg in weight. His temperature was 36.5 ℃, respiratory rate was 20 breaths/min, and blood pressure was 116/53 mmHg with a regular heart rate of 100 bpm. Thyroid palpation revealed that his thyroid was normal. Chest auscultation revealed that his lungs were clear and heart sounds were normal. Muscle strength of his left lower limb was grade 4, and that of the right lower and both upper limbs was grade 5.

***Laboratory examinations***

Laboratory investigations carried out at the time of presentation are summarized in Table 1. We confirmed the persistence of a hypokalemic state secondary to renal potassium wasting, while serum potassium levels remained at approximately 1.66–2.83 mmol/L, and urinary potassium excretion was increased from 102.43 to 120.08 mmol/d. Intriguingly, we observed hypomagnesemia (0.4 mmol/L), hypocalciuria (1.51-2.46 mmol/d), and metabolic alkalosis (7.47-7.54). Urinalysis did not show any alterations. Serum creatinine and creatinine clearance were slightly higher than normal. Glycosylated hemoglobin and plasma cortisol were within the normal range. Echocardiography and renal ultrasound did not show any abnormalities. Liver function, thyroid function, and other biochemical parameters were normal. Secondary hyperreninemic hyperaldosteronism was detected in the supine and upright positions (PRA 6.4 and 16.45 ng/mL/h and aldosterone 330.64 and 756.82 pg/mL, respectively) (Tables 2 and 3).

***Imaging examinations***

Computed tomography revealed hyperplasia at the junction of the left adrenal gland and calcification of the diverticulum in the right renal pelvis. Electrocardiography showed sinus rhythm and low T wave level.

**FINAL DIAGNOSIS**

The patient was diagnosed with hypokalemia, hypomagnesia, hypocalciuria, alkalosis, low serum chlorine, increased renin-angiotensin-aldosterone activity, normal blood calcium, and normal blood pressure. The detection of *SLC12A3* gene mutation confirmed the diagnosis of GS.

***Genetic testing***

The Guangzhou KingMed Center for Clinical Laboratory tested the genes of this patient, including the exon sequence of *SLC12A3* gene. The DNA extracted from the samples was tested by gene sequencing, and possible gene mutations were identified by comparing with the reference sequence. Two pathogenic mutations related to GS (Table 3) were detected: heterozygous rs768527231 Exon1 missense mutation C.248G>A (p.Asg83Gln), which is included in the dbSNP147 database, and Exon21 nonsense mutation C.2532G>A (p.Trp844\*), confirming the diagnosis of GS (Figure 1).

**TREATMENT**

Oral and intravenous supplementation with potassium and magnesium was initiated.

**OUTCOME AND FOLLOW-UP**

After treatment, the patient’s serum magnesium returned to 0.48 mmol/L, and serum potassium returned to 3.08 mmol/L. As a result, his fatigue symptoms were alleviated.

**DISCUSSION**

Hypokalemia is a common electrolyte disorder in clinical practice. Severe hypokalemia can lead to life-threatening reactions, such as dyspnea and arrhythmia. There are several causes of hypokalemia that can lead to insignificant limb weakness symptoms and can be easily ignored by patients; therefore, the diagnosis is challenging.

According to the etiopathogenesis, potassium deficiency due to inadequate intake and increased potassium excretion, hypokalemia, metastatic hypokalemia, and dilutive hypokalemia are included. The common causes of potassium deficiency in hypokalemia are inadequate potassium intake and excessive potassium loss in the digestive tract and kidney. Metastatic hypokalemia occurs when potassium is transferred from extracellular to intracellular, resulting in hypokalemia, in which the total amount of potassium is not deficient.

The diagnosis and differential diagnosis of hypokalemia was carried out. The patient was a young male with recurrent fatigue. Repeated blood potassium (3.5 mmol/L) and synchronous 24 h urine potassium excretion increased to > 25 mmol/d, indicating renal potassium loss. The patient had a normal appetite, adequate potassium intake, no history of using diuretics or a large dosage of insulin, and no long-term nausea, vomiting, and diarrhea; therefore, gastrointestinal loss was not considered. Metastatic hypokalemia was not supported as hyperthyroidism was absent and the patient’s blood glucose was normal. The patient had significantly elevated aldosterone levels, which excluded exogenous mineralocorticoid hyperplasia, Cushing syndrome, adrenal congenital 17-α/11-β hydroxylase deficiency, and Liddle syndrome. The patient’s blood pressure was normal, renin activity was increased, and no renal mass was observed. Primary aldosteronism and renin tumors were excluded. The patient did not have renal artery stenosis or proteinuria, and blood gas analysis suggested metabolic alkalosis. Therefore, renal tubular acidosis, renal artery stenosis, and chronic kidney disease were not considered. The patient developed the disease as an adult and was thin and small since childhood, which was related to long-term hypokalemia, with hypomagnesia, hypochloremia, and hypocalciuria. Genetic testing suggested a heterozygous variation in the *SLC12A3* gene. Two pathogenic mutations related to GS were detected in the *SLC12A3* gene region of the patient, including heterozygous rs768527231 Exon1 missense mutation C.248G > A (p.agsg83gln), which is included in the dbSNP147 database, and the Exon21 nonsense mutation C.2532g > A (p.TP844\*)[5], which was expected to change the amino acid position 844 of the encoded protein from Trp to stop codon, leading to protein translation terminated in advance. Based on these findings, the diagnosis of GS was established.

Furthermore, GS is an autosomal recessive genetic disorder, first described as an individual condition by Gitelman *et al* in 1966. GS can be attributed to structural and/or functional abnormalities of the sodium-chloride cotransporter (NCCT) due to the loss-of-function mutation in the gene *SLCI2A3*,encoding the thiazide diuretic sensitive NCCT located in the distal renal tubules[6].

Reduced sodium chloride reabsorption, blood volume, and renal salinization lower the blood pressure, activating the RAAS system and increasing aldosterone and renin levels, leading to hypokalemia and metabolic alkalosis. Decreased urinary calcium in GS patients may be associated with abnormal Na+/Cl- combined transport, weakening the intracellular Cl-superactivation, increasing CA2+ back absorption, and decreasing urinary calcium[4].

The decrease in serum magnesium level may be caused by increased Na+ reabsorption under the action of aldosterone, which results in the formation of luminal side negative potential and increases the level of urinary magnesium through increased Mg2+/Na+ exchange. This phenomenon may be related to the inactivation of transient receptor potential cation channel 6 (TRPM6) located at the apical domain of the distal convoluted tubules and brush border of the duodenal magnesium-transporter cells, resulting in decreased blood magnesium[7,8,10]. Simultaneously, hypomagnesemia can reduce the release of parathyroid hormone[7].

The mainstay of treatment for GS includes individualized lifelong administration of potassium and magnesium supplements (a strategy implemented in the present patient) combined with aldosterone antagonists and/or potassium-sparing agents, such as spironolactone, amiloride, and eplerenone to induce clinical remission.

A worldwide consensus[1,9] suggested that GS patients’ blood potassium and magnesium levels should be maintained at > 3.0 mmol/L and > 0.6 mmol/L, respectively.

This patient was mainly treated with potassium chloride and magnesium sulfate. After treatment, the patient’s clinical symptoms were relieved, but blood potassium did not reach the normal level; hence, regular follow-up was essential. GS is an autosomal recessive hereditary disease. Riveira-Munoz *et al*[11] suggested that the nature/position of *SLC12A3* mutation, combined with male gender, is a determining factor in the severity of GS. Therefore, investigation of the family by lineal gene testing is essential.

**CONCLUSION**

GS can be easily misdiagnosed or missed in diagnosis due to its low incidence and lack of awareness. Therefore, it is necessary to consider the possibility of GS in patients with clinical hypokalemia, low urinary calcium and low blood magnesium, and improve genetic screening for accurate diagnosis.

**REFERENCES**

1 **Knoers NV**. Gitelman syndrome. *Adv Chronic Kidney Dis* 2006; **13**: 148-154 [PMID: 16580616 DOI: 10.1053/j.ackd.2006.01.014]

2 **Melander O**, Orho-Melander M, Bengtsson K, Lindblad U, Râstam L, Groop L, Hulthén UL. Genetic variants of thiazide-sensitive NaCl-cotransporter in Gitelman's syndrome and primary hypertension. *Hypertension* 2000; **36**: 389-394 [PMID: 10988270 DOI: 10.1161/01.HYP.36.3.389]

3 **Tago N**, Kokubo Y, Inamoto N, Naraba H, Tomoike H, Iwai N. A high prevalence of Gitelman's syndrome mutations in Japanese. *Hypertens Res* 2004; **27**: 327-331 [PMID: 15198479 DOI: 10.1291/hypres.27.327]

4 **Kurtz I**. Molecular pathogenesis of Bartter's and Gitelman's syndromes. *Kidney Int* 1998; **54**: 1396-1410 [PMID: 9767561 DOI:10.1046/j.1523-1755.1998.00124.x]

5 **Lin SH**, Shiang JC, Huang CC, Yang SS, Hsu YJ, Cheng CJ. Phenotype and genotype analysis in Chinese patients with Gitelman's syndrome. *J Clin Endocrinol Metab* 2005; **90**: 2500-2507 [PMID: 15687331 DOI: 10.1210/jc.2004-1905]

6 **Yang W**, Zhao S, Xie Y, Mo Z. A novel SLC12A3 homozygous c2039delG mutation in Gitelman syndrome with hypocalcemia. *BMC Nephrol* 2018; **19**: 362 [PMID: 30558554 DOI: 10.1186/s12882-018-1163-3]

7 **Pantanetti P**, Arnaldi G, Balercia G, Mantero F, Giacchetti G. Severe hypomagnesaemia-induced hypocalcaemia in a patient with Gitelman's syndrome. *Clin Endocrinol (Oxf)* 2002; **56**: 413-418 [PMID: 11940055 DOI: 10.1046/j.1365-2265.2002.01223.x]

8 **Blanchard A**, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, Devuyst O, Ellison DH, Karet Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2017; **91**: 24-33 [PMID: 28003083 DOI: 10.1016/j.kint.2016.09.046]

9 **Gitelman Syndrome Collaborative Study Group**. Expert consensus for the diagnosis and treatment of patients with Gitelman syndrome. *Chin J Intern Med* 2017; **56**: 712-716 [DOI: 10.3760/cma.j.issn.0578-1426.2017.09.021]

10 **Jiang L**, Chen C, Yuan T, Qin Y, Hu M, Li X, Xing X, Lee X, Nie M, Chen L. Clinical severity of Gitelman syndrome determined by serum magnesium. *Am J Nephrol* 2014; **39**: 357-366 [PMID: 24776766 DOI: 10.1159/000360773]

11 **Riveira-Munoz E**, Chang Q, Godefroid N, Hoenderop JG, Bindels RJ, Dahan K, Devuyst O; Belgian Network for Study of Gitelman Syndrome. Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. *J Am Soc Nephrol* 2007; **18**: 1271-1283 [PMID: 17329572 DOI:10.1681/asn.2006101095]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 1, 2022

**First decision:** February 8, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lambrecht NW, United States; Mittal M, India; Thongon N, Thailand **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Figure Legends**

****

**Figure 1 Exon sequencing of pathogenic genes.**

**Table 1 Laboratory examinations**

|  |  |  |
| --- | --- | --- |
|  | **Value or range** | **Normal range** |
| Urinary pH | 8.5 | 5.0-8.4 |
| Urinary specific gravity | 1.01 | 1.021-1.03 |
| Urinary protein | Negative | Negative |
| BUN, mmol/L | 4.62 | 3.1-8 |
| CR, mmol/L | 76.3 | 57-97 |
| pH | 7.47-7.54 | 7.35-7.45 |
| HCO3-,mmol/L | 24.1-27.7 | 22-26 |
| Serum magnesium, mmol/L | 0.4 | 0.7-1.0 |
| Serum potassium, mmol/L | 1.66-2.83 | 3.5-5.3 |
| Serum sodium, mmol/L | 132.6-139.3 | 137-147 |
| Serum calcium, mmol/L | 2.21-2.36 | 2.11-2.52 |
| Serum phosphorus, mmol/L | 0.69 | 0.85-1.51 |
| Urinary potassium, mmol/d | 102.43-120.08 | 25-100 |
| Urinary calcium, mmol/d | 1.51-2.46 | 130-260 |
| Glycosylated hemoglobin, % | 5.5 | 4-6 |
| Parathyroid hormone, pg/mL | 8.67 | 14.5-87.1 |
| Cor, nmol/L (8 a.m.) | 287.17 | 6-10 a.m.: 133-537; |
| Cor, nmol/L (4 p.m.) | 151.73 | 4-8 p.m.: 68.2-327 |
| ACTH, pmol/L (8 a.m.) | 12.94 | 8 a.m., 4 p.m.: 2-14; |
| ACTH, pmol/L (4 p.m.) | 3.5 | 8 a.m., 4 p.m.: 2-14 |

BUN: Blood urea nitrogen; CR: Complete response; Cor: Cortisone; ACTH: Adreno-cortico-tropic-hormone.

**Table 2 Results of postural stimulation test**

|  |  |  |  |
| --- | --- | --- | --- |
| **Position** | **Aldosterone/(pg/mL)** | **Renin/(ng/mL/h)** | **ARR** |
| Clinostatism | 330.64 (40.0-310.0) | 6.4（0.15-2.33） | 5.36 (0-30) |
| Orthostatism | 756.82 (10.0-160.0) | 16.45 (1.31-3.95) | 4.6 (0-30) |

ARR: Aldosterone renin ratio.

**Table 3 Genetic testing**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Zone** | **Reference sequence** | **Location** | **cDNA level** | **Protein level** | **Status** | **Classification of variation** |
| *SLC12A3* | 16q13 | NM\_000339.2 | Exon1 | c.248G>A | p.*Arg83G1n* | Heterozygosis | Suspicious  pathologically |
| *SLC12A3* | 16q13 | NM\_000339.2 | Exon21 | c.2532G>A | p.*Trp844*\* | Heterozygosis | Pathological |